• Gene fusion; HGNC; HGNC:13575; BRD4 + HGNC; HGNC:29919; NUTM1; Name(s)=BRD4-NUTM1, BRD4-NUT (PubMed=23604113; PubMed=24736545).
  

PubMed=23604113; DOI=10.1038/onc.2013.126; PMCID=PMC3942361
Grayson A.R., Walsh E.M., Cameron M.J., Godec J., Ashworth T., Ambrose J.M., Aserlind A.B., Wang H., Evan G.I., Kluk M.J., Bradner J.E., Aster J.C., French C.A.
MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.
Oncogene 33:1736-1742(2014)

PubMed=24736545; DOI=10.1158/0008-5472.CAN-13-2658; PMCID=PMC4097982
Wang R.-R., Liu W., Helfer C.M., Bradner J.E., Hornick J.L., Janicki S.M., French C.A., You J.-X.
Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.
Cancer Res. 74:3332-3343(2014)

PubMed=30135075; DOI=10.1101/gad.315648.118; PMCID=PMC6120715
Liao S., Maertens O., Cichowski K.M., Elledge S.J.
Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.
Genes Dev. 32:1188-1200(2018)